Merck & Co., Inc. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0000310158

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltBuy & Hold how tags are computed

Q4 2024 · 13 positions · Total reported value $258.04M · Top-10 concentration 99.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 0.0% · 0 new · 0 cut · 0 exited

Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): +7.0% · vs SPY +4.9% · Prev Value $526.41M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +7.4% · vs SPY +5.2% · Latest Value $820.35M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2024 13F filing, Merck & Co., Inc. disclosed 13 equity positions with a combined reported value of $258.04M. The filing implies a focused portfolio: its ten largest positions account for 99.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / Buy & Hold.

The largest disclosed positions as of Q4 2024 were MRNA ($95.97M), PSNL ($81.18M), KYMR ($31.06M). By sector, the heaviest allocations are Health Care 99.3%, Other 0.7%.

Versus the prior quarter, Merck & Co., Inc. opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions.

The largest new positions opened in Q4 2024 were MRNA ($95.97M), PSNL ($81.18M), KYMR ($31.06M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • MRNA MODERNA INC · $95.97M
  • PSNL PERSONALIS INC · $81.18M
  • KYMR KYMERA THERAPEUTICS INC · $31.06M
  • TRDA ENTRADA THERAPEUTICS INC · $30.08M
  • ALEC ALECTOR INC · $6.70M
  • STRO SUTRO BIOPHARMA INC · $5.01M
  • ABSI ABSCI CORPORATION · $2.62M
  • VRDN VIRIDIAN THERAPEUTICS INC · $1.79M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Merck & Co., Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Merck & Co., Inc. is an SEC-registered 13F filer. As of Q2 2026 it reported 13 US equity positions with a combined value of $526.41M. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Portfolio Structure

  • 13 positions · $526.41M reported value (Q2 2026)
  • Top 10 holdings = 99.8% of reported value
  • Largest position: PSNL (PERSONALIS INC) at 35.8%
  • Average position size: $40.49M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 99.3%
Other 0.7%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.31M $95.97M 37.19%
37.19%
New
2 14.04M $81.18M 31.46%
31.46%
New
3 772.16K $31.06M 12.04%
12.04%
New
4 1.74M $30.08M 11.66%
11.66%
New
5 3.55M $6.70M 2.60%
2.60%
New
6 2.72M $5.01M 1.94%
1.94%
New
7 998.16K $2.62M 1.01%
1.01%
New
8 93.41K $1.79M 0.69%
0.69%
New
9 1.48M $1.42M 0.55%
0.55%
New
10 1.15M $1.09M 0.42%
0.42%
New
11 1.47M $616.99K 0.24%
0.24%
New
12 542.28K $458.44K 0.18%
0.18%
New
13 10.03K $34.39K 0.01%
0.01%
New

FAQ

What did Merck & Co., Inc. buy in 2024-Q4?

In its 2024-Q4 13F filing, Merck & Co., Inc. reported 13 equity positions worth $258.04M in aggregate; its largest disclosed positions were MRNA ($95.97M), PSNL ($81.18M), KYMR ($31.06M).

How large is Merck & Co., Inc.'s portfolio?

Merck & Co., Inc. reported $258.04M of long equity holdings across 13 positions as of 2024-Q4. Top-10 holdings account for 99.6% of reported value.

What is Merck & Co., Inc.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/merck-and/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →